Northwire Canada EditionFriday, July 17, 2026
Sign inSubscribe
Northwire
⌕
LUN 33.59 −2.5% NTR 94.27 −1.8% LALI 0.055 −8.3% SCD 0.170 +0.0% HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.095 −5.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.55 +1.8% LUN 33.59 −2.5% NTR 94.27 −1.8% LALI 0.055 −8.3% SCD 0.170 +0.0% HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.095 −5.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.55 +1.8%
M&A / Property

Pangea Provides Corporate Update on Peptide Products and Delivery System Pipeline

By The Northwire Desk — AI Analysis Oct 07, 2025 · 08:32 PNGA · 0.44 Pangea Natural Foods Inc.
PNGA · Price

Executive Summary

  • Pangea Natural Foods completed its Q2‑2025 acquisition of Amino Innovations Corp., adding a portfolio of needle‑free peptide therapeutics and related delivery technologies.
  • The company launched an eCommerce platform for the new peptide products, began influencer/clinic seeding campaigns, and disclosed early market metrics and product highlights (BPC, KPV, BLUE).
  • Development of patch and sublingual delivery system prototypes is underway, with bioavailability testing planned for Q4‑2025; a refreshed corporate website and investor materials were also released.

Key Details

  • Acquisition: Completed in Q2‑2025; Amino Innovations becomes a wholly‑owned subsidiary focused on non‑injectable peptide therapies.
  • Market Context: Global peptide therapeutics market valued at USD 117.26 bn (2024) and projected to reach USD 260.25 bn by 2030 (CAGR 10.77%). North America holds ~60% share.
  • Product Portfolio:
  • BPC – supports muscle recovery, joint health, gut balance.
  • KPV – promotes immune function and regulates inflammation.
  • BLUE – nootropic with methylene blue for focus, clarity, sustained energy.
  • Digital Launch: eCommerce platform went live June 2025 (www.aminoinnovations.com); early influencer and clinic partner seeding campaigns active; first wave of user‑generated content scheduled for September 2025.
  • Early Metrics Tracked: Subscription opt‑in rates, customer acquisition cost, cohort behavior, long‑term lifetime value.
  • Delivery System Development: Working patch prototype completed August 2025; Q4‑2025 partnership with third‑party labs to test bioavailability and efficacy of patch and sublingual formats.
  • Manufacturing: All products manufactured in the United States at a cGMP‑certified facility; select SKUs undergo third‑party quantitative stability and potency studies.
  • Corporate Materials: New website (pangeafood.com) and refreshed investor‑focused corporate materials launched to reflect health‑wellness focus post‑acquisition.

Notable Quotes

“The acquisition of Amino Innovations expands our capability to deliver innovative, clean‑label wellness solutions and positions Pangea at the forefront of the rapidly growing peptide therapeutics market.” – Pratap Sandhu, CEO, Corporate Secretary and Director.

Read the original news release →

More from Pangea Natural Foods Inc.

Dec 02, 2025 · 17:50

Pangea's Amino Innovations launches wholesale program

Other Nov 14, 2025 · 18:43

Pangea Natural Foods files amended financials, MD&A

Regulatory Oct 23, 2025 · 17:19

Pangea's Amino forms collab with U of A scientists

M&A / Property Oct 23, 2025 · 08:00

Amino Innovations Forms Strategic Research Partnership with University of Alberta Scientists to Advance Peptide Innovation

M&A / Property Oct 21, 2025 · 17:27

Pangea Natural develops new peptide patch

Other Oct 21, 2025 · 08:31

Amino Innovations Develops Next-Generation Peptide Patch Platform to Redefine Everyday Wellness

Other